Jun26 Appendix 4C Cash Flow Report
Filed with ASX · · 5 pages · English
Nexalis Therapeutics Limited on 6ix
Story so far
Earlier from Nexalis Therapeutics
- Update on Funding Facility and Clinical Program
- Binding Letter of Intent to replace existing $53m facility
- Suspension from Quotation
- Mar26 Appendix 4C Cash Flow Report
- Significant Milestone - First Patient Screened IRX-211 Ph2
Later from Nexalis Therapeutics
- Removal of draft wording in the directors report HY accounts
- Sep26 Quarterly Activities Report
- Sep26 Appendix 4C Cash Flow Report
Follow Nexalis Therapeutics into a list and get an email when it puts out news.
Follow Nexalis Therapeutics